CDKN2A and neoplasm: Treatment with Ad-ERE73 (1 + 2)-ARF (−13)-TK or Ad-ERE73 (3 + 4)-ARF (−13)-TK significantly reduced tumor volumes as compared to Ad-pless-TK or PBS (Figure 4B).